Enhancing Quality of Life and Wellness
A randomized, double-blind, cross-over, phase IV trial of Oros-Methylphenidate (Concerta®) and generic Novo-Methylphenidate ER-C (NOVO-generic). Accepted to Therapeutic Advances in Psychopharmacology.
Fallu A, Dabouz F, Furtado M, Anand L, Katzman MA
The noradrenergic paradox: implications in the management of depression and anxiety. Accepted to Neuropsychiatric Disease and Treatment.
Montoya A, Bruins R, Katzman MA, Blier P